Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: Potential use in an epidemic in Tajikistan

American Journal of Tropical Medicine and Hygiene

Volumn 61, Issue 1, 1999, Pages 163-170

  Tarr, Philip E ^d   Kuppens, Lianne ^d   Jones, Thomas C ^a   Ivanoff, Bernard ^b   Aparin, Petr G ^c   Heymann, David L ^d  

^a Clinical Research Consultants   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c INSTITUTE OF IMMUNOLOGY   (Russian Federation)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; COTRIMOXAZOLE; TYPHOID VACCINE;

ARTICLE; EPIDEMIC; HUMAN; MULTIDRUG RESISTANCE; PUBLIC HEALTH; SALMONELLA TYPHI; SANITATION; TAJIKISTAN; TYPHOID FEVER; VACCINATION;

EID: 0032781766     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.61.163     Document Type: Article

References (78)

1. Edelman R, Levine MM, 1986. Summary of an international workshop on typhoid fever. Rev Infect Dis 8: 329-349.
2. Ivanoff B, Levine MM, 1997. Typhoid fever: continuing challenges from a resilient bacterial foe. Bull Inst Pasteur 95: 129-142.
3. Rowe B, Ward LR, Threlfall EJ, 1997. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 24 (suppl 1): S106-S109.
4. Rowe B, Ward LR, Threlfall EJ, 1994. Ciprofloxacin-resistant Salmonella typhi in the UK. Lancet 346: 1302.
5. Murdoch DA, Banatvala NA, Bone A, Shoismatulloev BI, Ward LR, Threllfal EJ, 1998. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 351: 339.
6. Centers for Disease Control and Prevention, 1998. Epidemic typhoid fever-Dushanbe, Tajikistan, 1997. MMWR Morb Mortal Wkly Rep 47: 752-756.
7. Jesudason MV, John TJ, 1996. The concurrent prevalence of chloramphenicol-sensitive and multidrug-resistant Salmonella typhi in Vellore, S. India. Epidemiol Infect 116: 225-227.
8. Curschmann H, 1902. Typhoid Fever and Typhus Fever. Osler W, ed. Philadelphia and London: Saunders.
9. Bradley WH, Evans LW, Taylor I, 1953. A hospital outbreak of typhoid fever. J Hyg (Camb) 51: 324-334.
10. Bradaric N, Punda-Polic V, Milas I, Ivic I, Grgic D, Radosevic N, Petric I, 1996. Two outbreaks of typhoid fever related to the war in Bosnia and Herzegovina. Eur J Epidemiol 12: 409-412.
11. Hornick RB, 1985. Selective primary health care: strategies for control of disease in the developing world. XX. Typhoid fever. Rev Infect Dis 7: 536-546.
12. Wright AE, Semple D, 1897. Remarks on vaccination against typhoid fever. Br Med J: 256-259.
13. Pfeiffer R, Kolle W, 1896. Experimentelle Untersuchungen zur Frage der Schutzimpfung des Menschen gegen typhus abdominalis. Dtsch Med Wochenschr 22: 735-737.
14. Wright AE, 1902. On the results which have been obtained by anti-typhoid inoculation. Lancet 2: 651-654.
15. Wright AE, 1904. A Short Treatise on Antityphoid Inoculation. Westminster, UK: Constable.
16. Cockburn WC, 1955. The early history of typhoid vaccination. J R Army Med Corps 101: 171-185
17. Siler JF, Longfellow D, Luippold GF, 1941. Immunization to typhoid fever. Am J Hyg Monographic Series 17: 1-30.
18. Goldscheider, Kroner K, 1915. Ueber den Einfluss der Typhusschutzimpfungen auf die Typhuserkrankungen bei der Armee im Herbst und Winter 1914/15. Berl Klin Wochenschr 36: 933-940, 968-975, 1001-1004.
19. Basten J, 1920. Ausgedehnte Zwangsschutzimpfungen der Zivilbevoelkerung im besetzten Gebiet gegen Typhus. Die Frage des Manifestwerdens des Typhus im Anschluss an die Impfung. Dtsch Med Wochenschr 12: 316-318.
20. Batson HC, 1949. Typhoid fever prophylaxis by active immunization. Public Health Rep (suppl 212): 1-34.
21. Wilson GS, Miles A, eds, 1975. Enteric fever. Topley and Wilson's Principles of Bacteriology, Virology and Immunity. Volume 2. Sixth edition. Baltimore: Williams and Wilkins, 2005-2039.
22. Williams WC, Bishop EL, 1936. The typhoid control program and results of 13 years' work in Williamson county, Tennessee, 1922-35. Public Health Rep 51: 1-15.
23. Gay FP, 1918. The protective value of vaccination against typhoid fever. Gay FP, ed. Typhoid Fever Considered as a Problem of Scientific Medicine. New York: MacMillan Press, 172-197.
24. Hahn M, 1927. Mitteilungen zur Typhusepidemie in Hannover. Med Klin 27: 1009-1012.
25. Stroebe F, 1928. Typhus nach Typhusschutzimpfung ("Provokationstyphus"). Z Klin Med 108: 752-760.
26. Stowman K, 1948. Recrudescence of typhoid fever in Europe. Epidemiol Vit Stat Rep World Health Organ 1: 166-172.
27. Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P, 1987. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Infect Dis 9: 841-845.
28. Reisinger EC, Grasmug E, Krejs GJ, 1994. Antibody response after vaccination against typhoid fever in Kurdish refugee camp. Lancet 343: 918-919.
29. Yugoslav Typhoid Commission, 1964. A controlled field trial of the effectiveness of acetone-dried and inactivated and heat-phenol-inactivated typhoid vaccines in Yugoslavia. Bull World Health Organ 30: 623-630.
30. Polish Typhoid Commission, 1966. Controlled field trial and laboratory studies on the effectiveness of typhoid vaccines in Poland 1961-1964. Bull World Health Organ 34: 211-222.
31. Hejfec LB, Salmin LV, Lejtman MZ, Kuzminova ML, Vasileva AV, Levina LA, Bencjanova TG, Pavlova EA, Antonova AA, 1966. A controlled field trial and laboratory studies of five typhoid vaccines in the USSR. Bull World Health Organ 34: 321-339.
32. Ashcroft MT, Nicholoson CC, Balwant S, Ritchie JM, Sorvan E, William F, 1967. A seven year field trial of two typhoid vaccines in Guyana. Lancet 2: 1056-1060.
33. Tapa S, Cvjetanovic B, 1975. Controlled field trial on the effectiveness of one and two doses of acetone-inactivated and dried typhoid vaccine. Bull World Health Organ 52: 75-80.
34. Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D, Cadoz M, Armand J, 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 2: 1165-1169.
35. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, Schulz D, Armand J, Bryla DA, Trollfors B, 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 317: 1101-1104.
36. Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R, 1990. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Vaccine 8: 81-84.
37. Levine MM, Ferreccion C, Black RE, Germanier R, and the Chilean Typhoid Committee, 1987. Large-scale field trial of ty21a oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1: 1049-1052.
38. Levine MM, Ferreccio C, Cryz S, Ortiz E, 1990. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomized controlled field trial. Lancet 336: 891-894.
39. Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto R, Totosudirjo H, Haryanto P, Suprijanto E, Witham ND, Hoffman SL, 1991. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 338: 1055-1059.
40. Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R, 1982. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three year results. J Infect Dis 145: 292-295.
41. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R, and the Chilean Typhoid Committee, 1989. Progress in vaccines against typhoid fever. Rev Infect Dis 11 (suppl 3): S552-S567.
42. Ivanoff B, Levine MM, Lambert PH, 1994. Vaccination against typhoid fever: present status. Bull World Health Organ 72: 957-971.
43. Bernard RP, 1965. The Zermatt typhoid outbreak in 1963. J Hyg (Camb) 63: 537-563.
44. Walker W, 1965. The Aberdeen typhoid fever outbreak of 1964. Scott Med J 10: 466-474.
45. Feldman RE, Baine WB, Nitzin JL, Saslaw MS, Pollard RA, 1974: Epidemiology of Salmonella typhi infection in a migrant labor camp in Dade County, Florida. J Infect Dis 130: 334-341.
46. Stanwell-Smith RE, Ward LR, 1986. An international point source outbreak of typhoid fever: a European collaborative investigation. Bull World Health Organ 64: 271-278.
47. Dimache G, 1986. The comparative effectiveness, under epidemic conditions, of the intradermal versus subcutaneous antityphoid vaccination estimated by epidemiological surveillance and laboratory tests. Zentralbl Bakteriol Hyg A 262: 220-229.
48. Cryz Jr SJ, 1993. Post-marketing experience with live oral Ty21a vaccine. Lancet 341: 49-50.
49. Plotkin SA, Bouveret-LeCam N, 1995. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Intern Med 155: 2293-2299.
50. Robbins JD, Robbins JB, 1984. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis 150: 436-449.
51. Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB, 1994. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12: 195-199.
52. Klugman KP, Koornhof HJ, Robbins JB, LeCam NN, 1996. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14: 435-438.
53. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ, 1970. Typhoid fever: pathogenesis and immunological control. N Engl J Med 283: 686-691, 739-746.
54. Typhoid fever, 1985. Benenson AS, ed. 1985. Control of Communicable Disease in Man. 14th edition. Washington, D.C., American Public Health Association, 420-424.
55. Tran TH, Bethell DB, Nguyen TT, Wain J, To SD, Le TP, Bui MC, Nguyen MD, Pham T, 1995. Short course of ofloxacin for treatment of multidrug-resistant typhoid fever. Clin Infect Dis 20: 917-923.
56. Vinh H, Wain J, Vo TN, Cao NN, Mai TC, Behell DB, Nguyen TT, Tu SD, Nguyen MD, White NJ, 1996. Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children. Antimicrob Agents Chemother 40: 958-961.
57. Gotuzzo E, Guerra JG, Benavente L, Palomino JK, Carrillo C, Lopera J, Delgado F, Nalin DR, Sabbaj J, 1988. Use of norfloxacin to treat chronic typhoid carriers. J Infect Dis 157: 1221-1225.
58. Gotuzzo E, Carrillo C, 1994. Quinolones in typhoid fever. Infect Dis Clin Pract 3: 345-351.
59. Wain J, Hoa NTT, Chinh NT, Vinh H, Everett MJ, Diep TS, Day NPJ, Solomon T, White NJ, Piddock LJV, Parry CM, 1997. Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 25: 1404-1410.
60. Williams RJ, Heymann DL, 1998. Containment of antibiotic resistance. Science 279: 1153-1154.
61. Engels EA, Falagas ME, Lau J, Bennish ML, 1998. Typhoid fever vaccines: a meta-analysis of efficacy and toxicity studies. Br Med J 316: 110-116.
62. Szu SC, Taylor DN, Trofa AC, Clements JD, Shiloach J, Sadoff JC, Bryla DA, Robbbins JB, 1994. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 62: 4440-4444.
63. World Health Organisation, 1998. The Children's vaccine initiative (CVI) and WHO's global program for vaccines and immunizations (GPV). Recommendations from the scientific advisory group of experts (SAGE). Wkly Epidemiol Rec 73: 281-288.
64. Levine MM, Black RE, Lanata C, and the Chilean Typhoid Commitee, 1982. Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J Infect Dis 146: 724-726.
65. Topley JM, 1986. Mild typhoid fever. Arch Dis Child 61: 164-167.
66. Mahle WT, Levine MM, 1993. Salmonella typhi infection in children younger than five years of age. Pediatr Infect Dis J 12: 627-631.
67. Ferreccio C, Levine MM, Manterola A, Rodriguez G, Rivara I, Poenzel I, Black RE, Mancuso T, Bulas D, 1984. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. J Pediatr 104: 899-901.
68. Bhutta ZA, Naqvi SH, Razzaq RA, Farooqui BJ, 1991. Multidrug-resistant typhoid in children: presentation and clinical features. Rev Infect Dis 13: 832-836.
69. Toole MJ, Waldman RJ, 1993. Refugees and displaced persons. JAMA 270: 600-605.
70. Robbins JB, Schneerson R, Syu SC, 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171: 1387-1398.
71. Morris JG, Ferreccio C, Garcia J, Lobos H, Black RE, Rodriguez H, Levine MM, 1984. Typhoid fever in Santiago, Chile: a study of household contacts of pediatric patients. Am J Trop Med Hyg 33: 1198-1202.
72. Raettig HJ, 1959. Provokation einer Infektion durch Schutzimpfung. 3. Mitteilung: Schutzimpfung in einem endemisch verseuchten Maeusevolk. Zentralbl Bakteriol 175: 245-257.
73. Wilson GS, 1967. Indirect effects: provocation disease. Wilson GS, ed. The Hazards of Immunization. London: Athlone Press, 265-280.
74. Naficy A, Rao MR, Paquet C, Antona D, Sorkin A, Clemens JD, 1998. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings. A cost-effectiveness analysis. JAMA 279: 521-525.
75. Waldman RJ, 1998. Cholera vaccine in refugee settings. JAMA 280: 552-553.
76. Sack DA, 1998. Cholera vaccine in refugee settings (letter). JAMA 280: 600-601.
77. Jones TC, 1998. Will immunotherapy and vaccination replace antimicrobials - the future may be closer than we think. Braz J Infect Dis 2: 105-108.
78. Lin R, Tarr PE, Jones TC, 1995. Present status of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin Infect Dis 21: 1439-1449.